XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $753K invested in XTL Biopharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$801K |
| 2 |
Jane Street
New York
|
+$66K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.71K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$2.47K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Invesco
Atlanta,
Georgia
| $692K | +$801K | +6,491 | New |
|
|
2
Jane Street
New York
| $57K | +$66K | +535 | New |
|
|
U
3
UBS
Zurich,
Switzerland
| $2K | +$2.47K | +20 | New |
|
|
4
Ameriprise
Minneapolis,
Minnesota
| $2K | +$2.71K | +22 | New |
|
XTLB Hedge Fund Activity: Q3 2013 in Review
4 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2013, worth a combined $753K.
Buyers outnumbered sellers: 4 funds opened new XTLB positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $801K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $753K of XTL Biopharmaceuticals stock for Q3 2013.
- 4 funds opened new XTL Biopharmaceuticals positions in Q3 2013 and 0 closed out, a net change of +4 holders.
- The largest XTL Biopharmaceuticals buyer in Q3 2013 was Invesco, an estimated $801K added.
Based on aggregated 13F filings for Q3 2013.